Geron Corp (NASDAQ:GERN)

They have nothing left.

Baker Brothers took a position and the CEO recently bought. Good enough for me to take a flyer.

potential turn around story. heme cancer data at ASCO 13

2 cancer drugs below expectations. Stock will bounce back in the next few months.

Down too much today

There are currently 11000 GERN shares in my "fund" with break-even of around 2.65 USD. http://caps.fool.com/Blogs/fund-trades/678775.

down

stem cell research is the most promising new medical technology

Phase 2 study results pending and multi[le applications with core research should push to new highs

stem cell

stem cells are the future in medicine.

Give this 12 - 18 months and it will be $50/share. The down side or the depressing side is that it will trade between $5.25 and $4.70 until the day it takes off. 12% chance it fails.

Their current biomedical research has great potential, the next uptrend pike should not be far from now.

when i saw the article on the national news about the mouse that walked after treatment ,i looked to see if they were in a stock market and immediately purchased 6000 shares and have since then bought an additional 3000 . my take is simple what has worked in mice has worked in men plus the fact that i seemto have a knack for picking winners and this little gem is such a bargan at even 5 or 6 dollars yhat if this flys its going to go so high so fast your going to get a nose bleed.

this one I believe has a big growth story waiting on it-Im in at 5.74

cleared for fda clinical trials

Geron has developed a very broad, high-caliber pipeline and IP portfolio (please check out the company's website for specifics). The company has made significant prgress into early and mid-stage clinical trials on multiple fronts in Oncology and Regenerative Medicine. Geron's IP/pipeline represents a paradigm shift in the way human disease is treated. As such, progress has been a bit slower than may ordinarily be seen in development stage biotechs (and has understandably tested the patience of long-time investors). Nonetheless, with great risk comes (hopefully) great reward and all told Geron has done a remarkable job navigating largely uncharted terriitory in order to bring multiple programs in its pipeline into clinical trials (and against difficult market conditions over the last 10 years, no less). The company is starting to realize limited revenues from technology it co-developed with partners like GE Healthcare and Corning for scalable GMP cell culturing. This revenue won't fund the company but it will help with the need to raise additional capital as it moves to later stage (and eventually pivotal) clinical trials.

Although Geron's near and mid-term future has never looked better, it still represents a speculative investment. However, the breadth, depth and potential of its IP/pipeline make for compelling valuation in a company with a $600M market cap. I think its valuation is sufficently compelling to make a speculative investment with a long-term horizon. It wouldn't surprise me if a larger pharmaceutical company felt similarly. If so, current investors may be rewarded sooner than they might otherwise would have expected.

Stem cell research and stem cell implants are on the cusp of a great surge in price for the shares. There will be major breakthroughs in the upcoming weeks.

Latest stem cell hype could push this one up well.